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Introduction 
Toxic epidermal necrolysis (TEN), Stevens-Johnson 
syndrome (SJS), and SJS/TEN overlap comprise a 
spectrum of life-threatening, blistering, 
mucocutaneous disease. Toxic epidermal necrolysis 
is the rarest, representing the greatest amount of 
body surface area involvement. The majority of cases 
are attributed to drug reactions. We report a case of 
TEN in the setting of radiation therapy for a 
pleomorphic liposarcoma. 
Case Synopsis 
A 52-year-old man, with a recent diagnosis of 
pleomorphic liposarcoma, presented to the 
emergency department (ED) with a progressive rash 
and fever while undergoing neoadjuvant radiation 
therapy. He was scheduled to complete 30 sessions 
of radiotherapy, 5 days per week. Two days after his 
18th treatment he noted erythema and pain at his 
radiation site, which spread as a morbilliform rash 
across his body. Despite being started on prednisone 
60mg daily by his primary care physician, he 
developed oral mucosal erosions, difficulty 
swallowing, and hemoptysis prompting referral to 
the ED. His only other medications were long-
standing: lorazepam 0.5mg as needed for sleep and 
anxiety, senna and polyethylene glycol as needed for 
constipation, and ibuprofen 200mg as needed for 
pain. 
Physical examination at the time of evaluation 
revealed a surgical scar on the left lateral back with 
overlying blistering and detached skin, diffuse pink-
red macules over face and torso, dusky-centered 
papules over the lower extremities, superficial 
erosions of the soft palate, and vesicles of his lips 
(Figure 1). There was a positive Nikolsky sign. No 
appreciable cervical lymphadenopathy or scleral 
injection were present. 
Given these findings, he was suspected to have 
Stevens Johnson syndrome/Toxic epidermal 
necrolysis (SJS/TEN) and a SCORTEN (SCORE of Toxic 
epidermal necrolysis) of 3 given his age over 40 
years, body surface area detached >10%, and an  
Abstract 
Toxic epidermal necrolysis (TEN) and Stevens-
Johnson syndrome (SJS) are life-threatening, 
cutaneous reactions often associated with culprit 
drugs. A growing body of knowledge has deepened 
our understanding of the pathophysiology and 
clarified mechanisms such as drug-specific 
cytotoxicity mediated by T-cells, genetic linkage with 
HLA and non-HLA genes, TCR restriction, and 
cytotoxicity mechanisms. Physicians should broadly 
consider the etiology of SJS/TEN in order to better 
understand treatment strategies as well as identify 
which patients may be at risk for developing this 
condition. Mechanisms for how radiotherapy and 
rare malignancies may contribute to the 
development of TEN and SJS have been proposed. 
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associated malignancy. Therapy was promptly 
initiated with oral cyclosporine. A regimen of 
3mg/kg/d for 10 days followed by 2mg/kg/d for 10 
days, and finally, 1mg/kg/d for 10 days was 
recommended [1]. Herpes simplex viruses (HSV) 1 
and 2 IgM and Mycoplasma pneumoniae IgM titers 
were negative. 
During the course of his hospitalization, the eruption 
continued to progress to his distal extremities, 
genitalia, eyes ears, and face with involvement of 
over 30% of his body surface area (Figure 2). He 
received rigorous wound care in the burn center unit 
and was discharged on hospital day 11. 
The patient followed up with a surgical oncologist 
for definitive removal of his pleomorphic 
liposarcoma. Approximately 6 weeks following his 
discharge from the hospital he underwent radical 
resection of his pleomorphic liposarcoma on the 
back with reconstruction by the plastic surgery team.  
The pathology report revealed negative margins, 
four mitotic figures per 10 high power fields, and no 
lymphovascular invasion. Immunohistochemistry 
was focally positive for S100, focally weak-positive 
for SMA, negative for CK cocktail, CD24, myogenin, 
and desmin. Cytogenetics were negative for MDM2 
amplification. 
 
Case Discussion 
The mechanism of SJS and TEN is largely believed to 
be immune-mediated [2]. Over the last decade, the 
understanding of the pathophysiology of SJS and 
TEN has improved with the investigation and 
clarification of mechanisms such as drug-specific 
cytotoxicity mediated by T-cells, genetic linkage with 
HLA and non-HLA genes, TCR restriction, and 
cytotoxicity mechanisms [3]. The mechanisms for 
autoimmune and viral-induced forms of epidermal 
necrolysis not related to medication require further 
investigation [3]. In addition, there are multiple 
hypotheses for how radiation therapy may 
contribute to the development of SJS/TEN. For  
example, one hypothesis is that radiation may cause 
inhibition or deficiency of enzymes such as Figure 1. Early clinical presentation. Morbiliform rash covering 
back. 
Figure 2. Desquamation and progression to toxic epidermal 
necrolysis. Extension of affected body surface area along with 
sloughing skin and positive Nikolsky sign. 
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cytochrome P450, which would prevent the 
biotransformation of reactive metabolites and allow 
them to act as haptens that induce an immunologic 
response [4]. Another hypothesis is that SJS/TEN may 
develop after radiation owing to the release of 
antigenic factors as tumor cells are killed [5]. 
Additionally, radiation therapy is known to cause 
trauma to the skin and produce cutaneous reactions 
such as dermatitis. 
Although there are reported cases of TEN in patients 
receiving radiotherapy, the eruptions reported have 
occurred with concurrent use of anti-epileptic or 
chemotherapeutic agents. The only recent change in 
medication our patient noted was increased use of 
ibuprofen 200mg, which he had only been taking as 
needed. Stevens-Johnson syndrome/toxic epidermal 
necrolysis is not frequently reported in patients 
exposed to radiation therapy alone and similarly to 
this case, it is often difficult to ascertain if there is a 
culprit drug [3] There are reports of EM, SJS, and 
SJS/TEN overlap occurring with radiation alone, 
although many cases involved culprit medications as 
well [6]. In the majority of cases in irradiated patients, 
the rash originated at the site of radiation, much like 
in our patient [6, 7]. A gentleman receiving radiation 
therapy for non-small cell lung cancer even 
developed EM localized to his radiation port [7]. 
Toxic epidermal necrolysis has also been 
documented in the setting of infections and 
autoimmune disease [2, 3]. Mycoplasma pneumoniae 
infections have been associated with SJS and TEN in 
cases without culprit drugs [2]. The incidence of TEN 
is 1000-fold higher in patients with HIV than the 
general population [2]. The possibility of an 
autoimmune mechanism has led some authors to 
call for a distinction between a toxic and “non-toxic” 
form of epidermal necrolysis [3]. Several cases of TEN 
without a culprit drug have also been reported in the 
setting of an autoimmune condition [3]. In a UK-
based epidemiological study identifying risk factors 
for developing SJS/TEN (acknowledging that drug 
intake could be a confounding factor in some cases), 
lupus erythematosus, a well-established auto-
immune disease, was associated with SJS/TEN with 
an odds ratio of 16.0 [3]. 
In the same study, active cancer was also identified 
as a risk factor with an odds-ratio of 2.01 [3]. The 
potential for this rare malignancy to be involved in 
the etiology of this patient’s TEN should certainly be 
considered. Pleomorphic liposarcomas are rare high-
grade tumors capable of metastasis [8]. In a study of 
undifferentiated pleomorphic liposarcoma of the 
extremity and trunk specifically, Keung et al. 
demonstrated a trend towards increasing density of 
tumor immune infiltrate after radiotherapy, 
including CD3, CD4, CD8, FOXP3, and PD-L1 
expression [9]. Other cases of cutaneous reactions 
including SJS, have been reported after the 
utilization of nivolumab and pembrolizumab, which 
are programmed cell death receptor-1 (PD-1) 
antibodies, suggesting that the increased expression 
of PD-L1 and CD8+ cells can contribute to the 
development of erythema multiforme and SJS [10-
12]. Accentuation of the SJS in areas where the 
radiation therapy was administered has also been 
demonstrated in patients receiving anti-PD1 
immunotherapy both after and during radiation 
therapy for squamous cell carcinomas of the head 
and neck [11, 12]. 
 
Conclusion 
The potential for this rare malignancy to be involved 
in the etiology of this patient’s TEN should certainly 
be considered. This case reminds us that although 
SJS/TEN is often associated with a drug, our 
understanding of it is not yet complete. Physicians 
should broadly consider the etiology of SJS/TEN — a 
cutaneous reaction with multiple mechanisms at 
play — in order to better understand treatment 
strategies as well as predict which patients may be at 
risk for developing this condition. 
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